[ad_1]
Wall Street is setting a high bar for corporate earnings heading into second-quarter reporting season. The largest U.S. companies might struggle to clear it by a wide enough margin to impress investors.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...